Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | EPAS1 | Q99814 | 9/20 | 0.47 |
| ▸ | GPR3 | P46089 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30987223 | 0.75 | MAPT (0.60) | MAPTALDH1A1KDM4EHSD17B10EPAS1 | |
| SCHEMBL28563540 | 0.75 | MAPT (0.60) | MAPTALDH1A1KDM4EHSD17B10EPAS1 | |
| SCHEMBL2615998 | 0.73 | GRM4 (0.40) | MAPTALDH1A1KDM4EHSD17B10 | |
| SCHEMBL5985788 | 0.73 | MAPT (0.37) | MAPTALDH1A1KDM4EHSD17B10 | |
| SCHEMBL14303609 | 0.73 | CYP1A2 (0.41) | MAPTALDH1A1KDM4EHSD17B10GPR3 | |
| SCHEMBL4204967 | 0.71 | MAPT (0.56) | MAPTALDH1A1KDM4EHSD17B10EPAS1 | |
| SCHEMBL290849 | 0.71 | KDM4E (1.00) | MAPTALDH1A1KDM4EHSD17B10EPAS1 | |
| SCHEMBL329569 | 0.71 | MAPT (0.61) | MAPTALDH1A1KDM4EHSD17B10EPAS1 | |
| SCHEMBL3810651 | 0.71 | MAPT (0.56) | MAPTALDH1A1KDM4EHSD17B10EPAS1 | |
| SCHEMBL11654916 | 0.71 | MAPT (0.56) | MAPTALDH1A1KDM4EHSD17B10EPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1626 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109563190-A | The method of polymer is produced via emulsion polymerization | SABIC环球技术有限责任公司 | 2019-04-02 | — | — | CN | claimed |
| US-20250051692-A1 | Co-granules, washing and cleaning agents containing them and their use | CATEXEL GMBH (DE) | 2025-02-13 | — | — | US | disclosed |
| EP-4400172-A2 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | Incyte Holdings Corporation (US) | 2024-07-17 | — | — | EP | disclosed |
| EP-4400499-A1 | GLUTARIMIDE COMPOUND AND USE THEREOF | Medshine Discovery Inc. (CN) | 2024-07-17 | — | — | EP | disclosed |
| WO-2024141543-A1 | TRIARYLSULFONIUM BASED PHOTOINITIATORS FOR LED CURE OF CATIONIC, FREE RADICAL AND HYBRID CATIONIC/FREE RADICAL FORMULATIONS | ARKEMA FRANCE (FR) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024130342-A1 | TRANSIENT RECEPTOR POTENTIAL VANILLOID 6 INHIBITORS | UNIQUEST PTY LIMITED (AU) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024130217-A1 | STAPLED PEPTIDES AND METHODS THEREOF | FOG PHARMACEUTICALS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024121058-A1 | A COMPOSITION COMPRISING A LIPASE AND A PEPTIDE | NOVOZYMES A/S (DK) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024121057-A1 | A COMPOSITION FOR REMOVING BODY GRIME | NOVOZYMES A/S (DK) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024097355-A1 | DEUBIQUITINASE-TARGETING CHIMERAS AND RELATED METHODS | VICINITAS THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| EP-0646115-B1 | HETEROCYCLIC-CYCLIC AMINE DERIVATIVES | EISAI CO LTD (JP) | 2003-01-22 | — | — | EP | disclosed |
| WO-2003000181-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK & CO., INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| US-6498255-B2 | CHOLINESTERASE INHIBITORS; COGNITION ACTIVATORS; ALZHEIMER'S DISEASE; E.G., 3-(2-(1-(PHENYLMETHYL)-4-PIPERIDINYL)ETHYL)-1,2-BENZISOXAZOLE | PFIZER INC. | 2002-12-24 | — | — | US | disclosed |
| US-20020028834-A1 | Heterocyclic-cyclic amine derivatives | VILLALOBOS ANABELLA (US) | 2002-03-07 | — | — | US | disclosed |
| US-6326382-B1 | CHOLINESTERASE INHIBITORS; USEFUL IN ENHANCING MEMORY IN PATIENTS SUFFERING FROM DEMENTIA AND ALZHEIMER'S DISEASE | EISAI CO., LTD (JP) | 2001-12-04 | — | — | US | disclosed |
| US-5750542-A | Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors | PFIZER (US) | 1998-05-12 | — | — | US | disclosed |
| US-5538984-A | Methods of using piperidyl-benzisoxazole and benisothiazole derivatives as cholinesterase inhibitors | PFIZER INC. (US) | 1996-07-23 | — | — | US | disclosed |
| EP-0646115-A1 | HETEROCYCLIC-CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 1995-04-05 | — | — | EP | disclosed |
| WO-1992017475-A1 | HETEROCYCLIC-CYCLIC AMINE DERIVATIVES | PFIZER INC. (US) | 1992-10-15 | — | — | WO | disclosed |
| EP-0305529-A1 | TRIFLUOROMETHANESULFONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND HERBICIDES CONTAINING SAME | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1989-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028834-A1 | Heterocyclic-cyclic amine derivatives | BCHE, ACHE, CHRM1 | MAPT 81/4885ALDH1A1 1304/4885KDM4E 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.